Possible involvement of complement factor C1q in the clearance of extracellular neuromelanin from the substantia nigra in Parkinson disease

Journal of Neuropathology and Experimental Neurology

Volumn 70, Issue 2, 2011, Pages 125-132

  Depboylu, Candan ^a   Schäfer, Martin K H ^a   Arias Carrión, Oscar ^a   Oertel, Wolfgang H ^a   Weihe, Eberhard ^a   Höglinger, Günter U ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Complement system; Innate immune system; Microglia; Neurodegeneration; Parkinson disease; Phagocytosis

Indexed keywords

COMPLEMENT COMPONENT C1Q; NEUROMELANIN;

AGED; ARTICLE; BRAIN BLOOD VESSEL; BRAIN REGION; CELL ADHESION; CELL GRANULE; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EXTRACELLULAR SPACE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; MACROPHAGE; MALE; MICROGLIA; MOLECULAR RECOGNITION; NERVE CELL DEGENERATION; NEUROPATHOLOGY; PARENCHYMA; PARKINSON DISEASE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SUBSTANTIA NIGRA PARS COMPACTA;

AGED; AUTOPSY; COMPLEMENT C1Q; DIGOXIGENIN; EXTRACELLULAR SPACE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNITY, INNATE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MELANINS; PARKINSON DISEASE; PHAGOCYTOSIS; SUBSTANTIA NIGRA; TISSUE FIXATION; UP-REGULATION; URIDINE TRIPHOSPHATE;

EID: 79251600760     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e31820805b9     Document Type: Article

References (68)

1. Sellar GC, Blake DJ, Reid KB. Characterization and organization of the genes encoding the A-, B- and C-chains of human complement subcomponent C1q. The complete derived amino acid sequence of human C1q. Biochem J 1991;274:481-90
2. Gasque P. Complement: A unique innate immune sensor for danger signals. Mol Immunol 2004;41:1089-98
3. Mevorach D, Mascarenhas JO, Gershov D, et al. Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med 1998; 188:2313-20
4. Farkas I, Takahashi M, Fukuda A, et al. Complement C5a receptorY mediated signaling may be involved in neurodegeneration in Alzheimer's disease. J Immunol 2003;170:5764-71
5. Schäfer MK, Schwaeble WJ, Post C, et al. Complement C1q is dramatically up-regulated in brain microglia in response to transient global cerebral ischemia. J Immunol 2000;164:5446-52
6. Woodruff TM, Crane JW, Proctor LM, et al. Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB J 2006; 20:1407-17
7. Yamada T, Moroo I, Koguchi Y, et al. Increased concentration of C4d complement protein in the cerebrospinal fluids in progressive supra-nuclear palsy. Acta Neurol Scand 1994;89:42-46
8. Kovacs GG, Gasque P, Ströbel T, et al. Complement activation in human prion disease. Neurobiol Dis 2004;15:21-28
9. Barnett MH, Parratt JD, Cho ES, et al. Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann Neurol 2009;65:32-46
10. Depboylu C, Schäfer MK, Schwaeble WJ, et al. Increase of C1q biosynthesis in brain microglia and macrophages during lentivirus infection in the rhesus macaque is sensitive to antiretroviral treatment with 6-chloro-2¶,3¶-dideoxyguanosine. Neurobiol Dis 2005;20:12-26
11. Nguyen HX, Galvan MD, Anderson AJ. Characterization of early and terminal complement proteins associated with polymorphonuclear leukocytes in vitro and in vivo after spinal cord injury. J Neuroinflammation 2008;5:26
12. Klein MA, Kaeser PS, Schwarz P, et al. Complement facilitates early prion pathogenesis. Nat Med 2001;7:488-92
13. Ten VS, Yao J, Ratner V, et al. Complement component C1q mediates mitochondria-driven oxidative stress in neonatal hypoxic-ischemic brain injury. J Neurosci 2010;30:2077-87
14. Wyss-Coray T, Yan F, Lin AH, et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci USA 2002;99:10837-42
15. Rupprecht TA, Angele B, Klein M, et al. Complement C1q and C3 are critical for the innate immune response to Streptococcus pneumoniae in the central nervous system. J Immunol 2007;178:1861-69
16. Stevens B, Allen NJ, Vazquez LE, et al. The classical complement cascade mediates CNS synapse elimination. Cell 2007;131:1164-78
17. Färber K, Cheung G, Mitchell D, et al. C1q, the recognition subcomponent of the classical pathway of complement, drives microglial activation. J Neurosci Res 2009;87:644-52
18. Lynch NJ, Willis CL, Nolan CC, et al. Microglial activation and increased synthesis of complement component C1q precedes blood-brain barrier dysfunction in rats. Mol Immunol 2004;40:709-16
19. Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988;334:345-48
20. McGeer PL, Itagaki S, Boyes BE, et al. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988;38:1285-91
21. Imamura K, Hishikawa N, Sawada M, et al. Distribution of major his-tocompatibility complex class IIYpositive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol 2003:106:518-26
22. 11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 2006;21:404-12
23. Ouchi Y, Yoshikawa E, Sekine Y, et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 2005; 57:168-75
24. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: A target for neuroprotection? Lancet Neurol 2009;8:382-97
25. Breidert T, Callebert J, Heneka MT, et al. Protective action of the peroxisome proliferatorYactivated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 2002;82:615-24
26. Wu DC, Jackson-Lewis V, Vila M, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002;22:1763-71
27. Dufek M, Hamanová M, Lokaj J, et al. Serum inflammatory biomarkers in Parkinson's disease. Parkinsonism Relat Disord 2009;15:318-20
28. Rozemuller AJ, Eikelenboom P, Theeuwes JW, et al. Activated micro-glial cells and complement factors are unrelated to cortical Lewy bodies. Acta Neuropathol 2000;100:701-8
29. Yamada T, McGeer PL, McGeer EG. Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathol 1992;84:100-4
30. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51:745-52
31. Dietzschold B, Schwaeble W, Schäfer MK, et al. Expression of C1q, a subcomponent of the rat complement system, is dramatically enhanced in brains of rats with either Borna disease or experimental allergic enceph-alomyelitis. J Neurol Sci 1995;130:11-16
32. Schwaeble W, Schäfer MK, Petry F, et al. Follicular dendritic cells, interdigitating cells, and cells of the monocyte-macrophage lineage are the C1q-producing sources in the spleen. Identification of specific cell types by in situ hybridization and immunohistochemical analysis. J Immunol 1995;155:4971-78
33. Loos M, Martin H, Petry F. The biosynthesis of C1q, the collagen-like and Fc-recognizing molecule of the complement system. Behring Inst Mitt 1989;84:32-41
34. Lu J, Le Y, Kon OL, et al. Biosynthesis of human ficolin, an Escherichia coliYbinding protein, by monocytes: Comparison with the synthesis of two macrophage-specific proteins, C1q and the mannose receptor. Immunology 1996;89:289-94
35. Müller W, Hanauske-Abel H, Loos M. Biosynthesis of the first component of complement by human and guinea pig peritoneal macrophages: Evidence for an independent production of the C1 subunits. J Immunol 1978;121:1578-84
36. Petry F, Botto M, Holtappels R, et al. Reconstitution of the complement function in C1q-deficient (C1qaj/j) mice with wild-type bone marrow cells. J Immunol 2001;167:4033-37
37. Fonseca MI, Kawas CH, Troncoso JC, et al Neuronal localization of C1q in preclinical Alzheimer's disease. Neurobiol Dis 2004;15:40-46
38. Thomas A, Gasque P, Vaudry D, et al. Expression of a complete and functional complement system by human neuronal cells in vitro. Int Immunol 2000;12:1015-23
39. Veerhuis R, Janssen I, De Groot CJ, et al. Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor. Exp Neurol 1999;160:289-99
40. Spielman L, Winger D, Ho L, et al. Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2. Acta Neuropathol 2002;103:157-62
41. Mack WJ, Sughrue ME, Ducruet AF, et al. Temporal pattern of C1q deposition after transient focal cerebral ischemia. J Neurosci Res 2006; 83:883-89
42. Shen Y, Li R, McGeer EG, et al. Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res 1997;769:391-95
43. Eggleton P, Tenner AJ, Reid KB. C1q receptors. Clin Exp Immunol 2000;120:406-12
44. Kishore U, Reid KB. C1q: Structure, function, and receptors. Immunopharmacology 2000:49:159-70
45. Rudow G, O'Brien R, Savonenko AV, et al. Morphometry of the human substantia nigra in ageing and Parkinson's disease. Acta Neuropathol 2008;115:461-70
46. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 1991;114:2283-301
47. Mann DM, Yates PO. Possible role of neuromelanin in the pathogenesis of Parkinson's disease. Mech Ageing Dev 1983;21:193-203
48. Tompkins MM, Basgall EJ, Zamrini E, et al. Apoptotic-like changes in Lewy-bodyYassociated disorders and normal aging in substantia nigral neurons. Am J Pathol 1997;150:119-31
49. Ma SY, Röytt M, Collan Y, et al. Unbiased morphometrical measurements show loss of pigmented nigral neurones with ageing. Neuropathol Appl Neurobiol 1999;25:394-99
50. Fraser DA, Pisalyaput K, Tenner AJ. C1q enhances microglial clearance of apoptotic neurons and neuronal blebs, and modulates subsequent inflammatory cytokine production. J Neurochem 2010;112:733-43
51. Zhang ET, Richards HK, Kida S, et al. Directional and compartmentalised drainage of interstitial fluid and cerebrospinal fluid from the rat brain. Acta Neuropathol 1992;83:233-39
52. Hochmeister S, Zeitelhofer M, Bauer J, et al. After injection into the striatum, in vitroYdifferentiated microglia- and bone marrowYderived dendritic cells can leave the central nervous system via the blood stream. Am J Pathol 2008;173:1669-81
53. Depboylu C, Matusch A, Tribl F, et al. Glia protects neurons against extracellular human neuromelanin. Neurodegener Dis 2007;4:218-26
54. Reynolds AD, Glanzer JG, Kadiu I, et al. Nitrated alpha-synucleinY activated microglial profiling for Parkinson's disease. J Neurochem 2008; 104:1504-25
55. Wilms H, Rosenstiel P, Sievers J, et al. Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: Implications for Parkinson's disease. FASEB J 2003;17:500-2
56. Zhang W, Wang T, Pei Z, et al. Aggregated alpha-synuclein activates microglia: A process leading to disease progression in Parkinson's disease, FASEB J 2005;19:533-42
57. Zecca L, Wilms H, Geick S, et al. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: Implications for Parkinson's disease. Acta Neuropathol 2008;116:47-55
58. Croisier E, Moran LB, Dexter DT, et al. Microglial inflammation in the parkinsonian substantia nigra: Relationship to alpha-synuclein deposition. J Neuroinflammation 2005;2:14
59. Beach TG, Sue LI, Walker DG, et al. Marked microglial reaction in normal aging human substantia nigra: Correlation with extraneuronal neuromelanin pigment deposits. Acta Neuropathol 2007;114:419-24
60. Benner EJ, Banerjee R, Reynolds AD, et al. Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One 2008;3:e1376
61. Papachroni KK, Ninkina N, Papapanagiotou A, et al. Autoantibodies to alpha-synuclein in inherited Parkinson's disease. J Neurochem 2007;101: 749-56
62. Liberatore GT, Jackson-Lewis V, Vukosavic S, et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999;5:1403-9
63. Langston JW, Forno LS, Tetrud J, et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine exposure. Ann Neurol 1999; 46:598-605
64. McGeer PL, Schwab C, Parent A, et al. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann Neurol 2003;54:599-604
65. Griffiths MR, Gasque P, Neal JW. The multiple roles of the innate immune system in the regulation of apoptosis and inflammation in the brain. J Neuropathol Exp Neurol 2009;68:217-26
66. Lu J, Wu X, Teh BK. The regulatory roles of C1q. Immunobiology 2007; 212:245-52
67. Dodel R, Spottke A, Gerhard A, et al. Minocycline 1-year therapy in multiple-system-atrophy: Effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord 2010;25:97-107
68. Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: A phase III randomised trial. Lancet Neurol 2007;6:1045-53